Published in Eur J Endocrinol on March 01, 2008
Acute thyroid eye disease (TED): principles of medical and surgical management. Eye (Lond) (2013) 1.40
The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. Eur Thyroid J (2016) 1.11
The eye and thyroid disease. Curr Opin Ophthalmol (2008) 1.05
EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging (2010) 1.02
Incidence and clinical presentation of moderate to severe graves' orbitopathy in a Danish population before and after iodine fortification of salt. J Clin Endocrinol Metab (2012) 0.99
Inflammatory cytokine profiles in the tears of thyroid-associated ophthalmopathy. Graefes Arch Clin Exp Ophthalmol (2011) 0.93
Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol (2013) 0.91
Increased serum interleukin-17 in Graves' ophthalmopathy. Graefes Arch Clin Exp Ophthalmol (2012) 0.91
Graves' orbitopathy: imperfect treatments for a rare disease. Eur Thyroid J (2013) 0.90
Liver Dysfunction Associated with Intravenous Methylprednisolone Pulse Therapy in Patients with Graves' Orbitopathy. Int J Endocrinol (2015) 0.86
Diagnostic accuracy of short-time inversion recovery sequence in Graves' Ophthalmopathy before and after prednisone treatment. Neuroradiology (2014) 0.86
Disease activity in Graves' ophthalmopathy: diagnosis with orbital MR imaging and correlation with clinical score. Neuroradiol J (2013) 0.85
Feasibility of tomotherapy for Graves' ophthalmopathy: Dosimetry comparison with conventional radiotherapy. Strahlenther Onkol (2011) 0.85
Graves' orbitopathy: Management of difficult cases. Indian J Endocrinol Metab (2012) 0.83
Relevance of TSH-receptor antibody levels in predicting disease course in Graves' orbitopathy: comparison of the third-generation TBII assay and Mc4-TSI bioassay. Eye (Lond) (2013) 0.81
Graves' Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management. J Ophthalmol (2015) 0.81
Update on advanced imaging options for thyroid-associated orbitopathy. Saudi J Ophthalmol (2012) 0.80
A retrospective study on the efficacy of total absorbed orbital doses of 12, 16 and 20 Gy combined with systemic steroid treatment in patients with Graves' orbitopathy. Graefes Arch Clin Exp Ophthalmol (2009) 0.80
Effects of treatment modalities for Graves' hyperthyroidism on Graves' orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement. J Endocrinol Invest (2015) 0.80
Inhibitory Effects of α-Lipoic Acid on Oxidative Stress-Induced Adipogenesis in Orbital Fibroblasts From Patients With Graves Ophthalmopathy. Medicine (Baltimore) (2016) 0.80
PPARg2 Ala¹² variant protects against Graves' orbitopathy and modulates the course of the disease. Immunogenetics (2013) 0.80
Effect of radiotherapy on moderate and severe thyroid associated ophthalmopathy: a double blind and self-controlled study. Int J Clin Exp Med (2015) 0.80
Development of criteria for evaluating clinical response in thyroid eye disease using a modified Delphi technique. Arch Ophthalmol (2009) 0.79
Orbital decompression for Graves' orbitopathy in England. Eye (Lond) (2011) 0.79
Thyroid-associated orbitopathy is linked to gastrointestinal autoimmunity. Clin Exp Immunol (2014) 0.79
A 2015 Italian Survey of Clinical Practice Patterns in the Management of Graves' Disease: Comparison with European and North American Surveys. Eur Thyroid J (2016) 0.79
Graves' disease is associated with a defective expression of the immune regulatory molecule galectin-9 in antigen-presenting dendritic cells. PLoS One (2015) 0.78
Use of MRI signal intensity of extraocular muscles to evaluate methylprednisolone pulse therapy in thyroid-associated ophthalmopathy. Jpn J Ophthalmol (2014) 0.78
Therapy: evidence-based treatment of Graves ophthalmopathy. Nat Rev Endocrinol (2009) 0.78
[Update on endocrine orbitopathy]. Ophthalmologe (2013) 0.78
Greater Efficacy of Total Thyroidectomy versus Radioiodine Therapy on Hyperthyroidism and Thyroid-Stimulating Immunoglobulin Levels in Patients with Graves' Disease Previously Treated with Antithyroid Drugs. Eur Thyroid J (2012) 0.77
Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy. J Endocrinol Invest (2015) 0.77
Changes of orbital tissue volumes and proptosis in patients with thyroid extraocular muscle swelling after methylprednisolone pulse therapy. Jpn J Ophthalmol (2015) 0.77
Efficacy of combined orbital radiation and systemic steroids in the management of Graves' orbitopathy. Graefes Arch Clin Exp Ophthalmol (2016) 0.77
Thyrotropin receptor and CD40 mediate interleukin-8 expression in fibrocytes: implications for thyroid-associated ophthalmopathy (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc (2014) 0.77
Graves orbitopathy: a perspective. Nat Rev Endocrinol (2009) 0.77
The influence of prior hyperthyroidism on euthyroid graves' ophthalmopathy. J Ophthalmol (2014) 0.76
Platelet-derived growth factor: a key factor in the pathogenesis of graves' ophthalmopathy and potential target for treatment. Eur Thyroid J (2014) 0.76
The influence of hepatitis C infection and interferon-alpha therapy on thyrotropin blocking and stimulating autoantibodies in Graves' ophthalmopathy: a case report. Thyroid Res (2009) 0.76
Onset of Graves' disease during long-term immunosuppressive therapy in a patient with membranous nephropathy. Endocrinol Diabetes Metab Case Rep (2015) 0.75
Methylprednisolone Pulse Treatment of Graves' Ophthalmopathy Is Not Associated with Secondary Adrenocortical Insufficiency. Eur Thyroid J (2015) 0.75
Safety Profile and Effects of Pulsed Methylprednisolone on Vital Signs in Thyroid Eye Disease. Int J Endocrinol (2015) 0.75
Corneal biomechanical changes and intraocular pressure in patients with thyroid orbitopathy. Int J Ophthalmol (2016) 0.75
Predictive Factors of Development of Graves' Ophthalmopathy for Patients with Juvenile Graves' Disease. Int J Endocrinol (2016) 0.75
Nicotinamide phosphoribosyltransferase leukocyte overexpression in Graves' opthalmopathy. Endocrine (2016) 0.75
Clinical and imaging evaluation of the response to intravenous steroids in patients with Graves' orbitopathy and analysis on who requires additional therapy. Clin Ophthalmol (2016) 0.75
Rituximab therapy in steroid-resistant severe hypothyroid Grave's ophthalmopathy. Indian J Endocrinol Metab (2013) 0.75
Improved Vision from Severe Compressive Optic Neuropathy by Apical Cavernous Hemangioma. Case Rep Ophthalmol (2016) 0.75
CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves' disease and modulates clinical phenotype of disease. Endocrine (2016) 0.75
Efficacy of Subantimicrobial Dose Doxycycline for Moderate-to-Severe and Active Graves' Orbitopathy. Int J Endocrinol (2015) 0.75
Severe eyelid oedema in Graves' ophthalmopathy. BMJ Case Rep (2013) 0.75
The association of carotid cavernous fistula with Graves' ophthalmopathy. Indian J Ophthalmol (2013) 0.75
Prevalence of Graves' ophthalmopathy in patients with Graves' disease presenting to a referral centre in north India. Indian J Med Res (2014) 0.75
Comparison of Early Total Thyroidectomy with Antithyroid Treatment in Patients with Moderate-Severe Graves' Orbitopathy: A Randomized Prospective Trial. Eur Thyroid J (2016) 0.75
Short and long-term effects of high-dose intravenous methylprednisolone pulse therapy on thyroid-associated ophthalmopathy. Exp Ther Med (2016) 0.75
Relationship between magnetic resonance imaging signal intensity and volume of extraocular muscles in thyroid-associated ophthalmopathy with methylprednisolone pulse therapy. Clin Ophthalmol (2016) 0.75
Effect of smoking on retrobulbar blood flow in thyroid eye disease. Eye (Lond) (2016) 0.75
Diagnosis, Follow-Up and Treatment Results in Thyroid Ophthalmopathy. Turk J Ophthalmol (2015) 0.75
Cervical lymph nodes, thyroiditis and ophthalmopathy: the pleomorphic face of an immunoglobulin g4-related disease. Eur Thyroid J (2014) 0.75
Evaluation of retinal nerve fiber layer thickness profile in thyroid ophthalmopathy without optic nerve dysfunction. Int J Ophthalmol (2016) 0.75
Shopping for doctors: Thyroid eye disease patients are never satisfied. Oman J Ophthalmol (2011) 0.75
Guidance on That Damned Elusive Orbitopathy of Graves' Disease. Eur Thyroid J (2016) 0.75
Management of patients in a combined thyroid eye clinic in secondary care. Int Ophthalmol (2013) 0.75
[Surgical therapy in Graves' orbitopathy]. Ophthalmologe (2011) 0.75
Enhanced-depth optical coherence tomography for imaging horizontal rectus muscles in Graves' orbitopathy. Graefes Arch Clin Exp Ophthalmol (2015) 0.75
Dysthyroid optic neuropathy: update on pathogenesis, diagnosis, and management. Expert Rev Ophthalmol (2017) 0.75
Fornix triamcinolone injection for thyroid orbitopathy. Graefes Arch Clin Exp Ophthalmol (2015) 0.75
[Drug therapy and radiotherapy in Graves' orbitopathy]. Ophthalmologe (2011) 0.75
[Driving competency after combined treatment with methylprednisolone and orbital radiotherapy for endocrine orbitopathy]. Ophthalmologe (2010) 0.75
[Graves' ophthalmopathy]. Ophthalmologe (2016) 0.75
Update on thyroid-associated Ophthalmopathy with a special emphasis on the ocular surface. Clin Diabetes Endocrinol (2016) 0.75
[Clinical and neuroradiological diagnostics in Graves' orbitopathy]. Ophthalmologe (2011) 0.75
Risk of thyroid cancer after exposure to 131I in childhood. J Natl Cancer Inst (2005) 5.32
Iodine status of UK schoolgirls: a cross-sectional survey. Lancet (2011) 4.96
Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2012) 4.64
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab (2008) 3.38
Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med (2010) 3.24
Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. J Clin Invest (2007) 3.20
Selenium and the course of mild Graves' orbitopathy. N Engl J Med (2011) 3.06
Cancer consequences of the Chernobyl accident: 20 years on. J Radiol Prot (2006) 3.03
Europe is iodine deficient. Lancet (2003) 2.99
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol (2009) 2.77
Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab (2007) 2.74
Human laminin beta2 deficiency causes congenital nephrosis with mesangial sclerosis and distinct eye abnormalities. Hum Mol Genet (2004) 2.67
Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid (2008) 2.65
Blindness following cosmetic injections of the face. Plast Reconstr Surg (2012) 2.41
Clinical relevance of thyroid-stimulating immunoglobulins in graves' ophthalmopathy. Ophthalmology (2011) 2.23
Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients. Diabetes Care (2008) 2.22
Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab (2005) 2.13
Low-dose tissue plasminogen activator in the management of anterior chamber fibrin formation. J Cataract Refract Surg (2003) 2.07
Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab (2014) 1.98
Cognitive ability and brain structure in type 1 diabetes: relation to microangiopathy and preceding severe hypoglycemia. Diabetes (2003) 1.97
Mutations in prokineticin 2 and prokineticin receptor 2 genes in human gonadotrophin-releasing hormone deficiency: molecular genetics and clinical spectrum. J Clin Endocrinol Metab (2008) 1.92
Studying global change through investigation of the plastic responses of xylem anatomy in tree rings. New Phytol (2009) 1.88
A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. J Clin Endocrinol Metab (2004) 1.87
Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol (2010) 1.86
Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab (2004) 1.82
Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab (2002) 1.81
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab (2004) 1.79
Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab (2004) 1.75
Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. J Clin Endocrinol Metab (2003) 1.74
Influence of an early-onset age of type 1 diabetes on cerebral structure and cognitive function. Diabetes Care (2005) 1.72
Familial dysalbuminemic hyperthyroxinemia: a persistent diagnostic challenge. Clin Chem (2009) 1.71
Minimally invasive video-assisted thyroidectomy for papillary carcinoma: a prospective study of its completeness. Surgery (2002) 1.71
New star on the stage: amount of ray parenchyma in tree rings shows a link to climate. New Phytol (2013) 1.70
Relative potencies and additivity of perchlorate, thiocyanate, nitrate, and iodide on the inhibition of radioactive iodide uptake by the human sodium iodide symporter. Thyroid (2004) 1.69
Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis (2011) 1.67
The environment and autoimmune thyroid diseases. Eur J Endocrinol (2004) 1.66
In vivo analysis of conjunctiva in gold micro shunt implantation for glaucoma. Br J Ophthalmol (2010) 1.66
Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J Clin Endocrinol Metab (2010) 1.63
The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab (2012) 1.62
Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res (2002) 1.58
Comparison of mesenchymal stem cells from bone marrow and adipose tissue for bone regeneration in a critical size defect of the sheep tibia and the influence of platelet-rich plasma. Biomaterials (2010) 1.58
Comparison of a new-generation sectorial addition multifocal intraocular lens and a diffractive apodized multifocal intraocular lens. J Cataract Refract Surg (2011) 1.58
Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab (2004) 1.58
Technical evaluation of the first fully automated assay for the detection of TSH receptor autoantibodies. Clin Chim Acta (2008) 1.56
Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med (2003) 1.55
The removal of the deep lateral wall in orbital decompression: its contribution to exophthalmos reduction and influence on consecutive diplopia. Am J Ophthalmol (2005) 1.55
Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab (2009) 1.54
Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of differentiated thyroid cancer patients. J Clin Endocrinol Metab (2004) 1.52
Early versus late orbital decompression in Graves' orbitopathy: a retrospective study in 125 patients. Ophthalmology (2006) 1.51
Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab (2007) 1.51
Subclinical hypothyroidism: the case for treatment. Trends Endocrinol Metab (2003) 1.51
Enhancement of the core near-band-edge emission induced by an amorphous shell in coaxial one-dimensional nanostructure: the case of SiC/SiO2 core/shell self-organized nanowires. Nanotechnology (2010) 1.50
Analytical performance and clinical utility of a bioassay for thyroid-stimulating immunoglobulins. Am J Clin Pathol (2013) 1.50
Genomic polymorphism at the interferon-induced helicase (IFIH1) locus contributes to Graves' disease susceptibility. J Clin Endocrinol Metab (2007) 1.49
Association of the TSHR gene with Graves' disease: the first disease specific locus. Eur J Hum Genet (2005) 1.49
Risk factors for and prevalence of thyroid disorders in a cross-sectional study among healthy female relatives of patients with autoimmune thyroid disease. Clin Endocrinol (Oxf) (2003) 1.48
Perchlorate and thiocyanate exposure and thyroid function in first-trimester pregnant women. J Clin Endocrinol Metab (2010) 1.47
Clinical and endocrine responses to pituitary radiotherapy in pediatric Cushing's disease: an effective second-line treatment. J Clin Endocrinol Metab (2003) 1.47
Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey. Br J Ophthalmol (2006) 1.45